SG11201810580PA - Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement - Google Patents
Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplementInfo
- Publication number
- SG11201810580PA SG11201810580PA SG11201810580PA SG11201810580PA SG11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA SG 11201810580P A SG11201810580P A SG 11201810580PA
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- international
- lipids
- carbon atoms
- odd number
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title abstract 4
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 8
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 241000737286 Ophioglossum Species 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000003925 brain function Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 239000009853 xinfeng Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT omit VIII Hot o 01 OH OH om olo mo Immo oimIE (10) International Publication Number WO 2017/211274 Al (51) International Patent Classification: A61K 31/215 (2006.01) A61P 21/00 (2006.01) A61K 31/22 (2006.01) A61P 13/12 (2006.01) A61P 25/28 (2006.01) A61P 3/10 (2006.01) A61P 25/02 (2006.01) A61P 11/06 (2006.01) A61P 25/00 (2006.01) A61Q 19/08 (2006.01) A61P 9/10 (2006.01) (21) International Application Number: PCT/CN2017/087341 (22) International Filing Date: 06 June 2017 (06.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/347,103 08 June 2016 (08.06.2016) US (72) Inventors; and (71) Applicants: DONG, Yuhong [CN/CH]; Robinienweg 51, 4153 Reinach, Basel-land (CH). CHANG, Chun-Hsiung [CN/CN]; No.459, Sec. 1, Zhongshan Rd., Huatan Town- ship, Changhua County, Taiwan 50343 (CN). (72) Inventors: DONG, Yuhong; Robinienweg 51, 4153 Reinach, Basel-land (CH). CHANG, Chun-Hsiung; No.459, Sec. 1, Zhongshan Rd., Huatan Township, Changhua County, Taiwan 50343 (CN). (74) Agent: CCTW INTELLECTUAL PROPERTY AGENCY LTD; Room A810, Tiancheng Technology Building, No.2 Xinfeng Street, Xicheng District, Beijing 100088 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS PHARMACEUTICAL COMPOSITION OR NUTRITIONAL SUPPLEMENT (57) : Provided are the use of lipids bearing fatty acids with an odd number of carbon atoms as pharmaceuticals or nutritional supplement. In particular, such lipids are used in the treatment and/or prevention of neurodegenerative diseases, optic and retinal degenerative diseases, demyelinating diseases, neuromuscular disorders and muscular dystrophy, brain or spinal cord nerve injury, amyloid related diseases, otherchronic diseases selected from kidney diseases, diabetes or asthma, but also a functional food or food supplement for anti-aging or life-span prolongation and brainfunction improvement for human and/or animals. Moreover, provided is the herb Ophioglossum which can be used for the treatment and/or prevention of said diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347103P | 2016-06-08 | 2016-06-08 | |
| PCT/CN2017/087341 WO2017211274A1 (en) | 2016-06-08 | 2017-06-06 | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810580PA true SG11201810580PA (en) | 2018-12-28 |
Family
ID=60577583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810580PA SG11201810580PA (en) | 2016-06-08 | 2017-06-06 | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11406616B2 (en) |
| EP (1) | EP3468551A4 (en) |
| JP (2) | JP6872805B2 (en) |
| KR (1) | KR20190017873A (en) |
| CN (2) | CN117298092A (en) |
| AU (1) | AU2017277005B2 (en) |
| CA (1) | CA3026152A1 (en) |
| CL (1) | CL2018003537A1 (en) |
| MX (1) | MX2018015188A (en) |
| NZ (1) | NZ749389A (en) |
| SG (1) | SG11201810580PA (en) |
| TW (1) | TWI749016B (en) |
| WO (1) | WO2017211274A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019052629A1 (en) * | 2017-09-12 | 2019-03-21 | Sunregen Healthcare Ag | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
| CN111773351A (en) * | 2019-09-20 | 2020-10-16 | 厦门医学院 | Application of coleus blumei and curcuma longa composition in preparation of medicine composition for reducing blood sugar and blood pressure |
| CN111773274A (en) * | 2019-09-20 | 2020-10-16 | 厦门医学院 | Application of coleus blumei and plantain seed composition in preparation of pharmaceutical composition for reducing blood sugar and blood pressure |
| WO2021107084A1 (en) * | 2019-11-27 | 2021-06-03 | リファインホールディングス株式会社 | Insulin secretion-promoting agent and blood sugar level improver using same, diabetes improver, and food |
| EP4355316A1 (en) * | 2021-06-18 | 2024-04-24 | SunRegen Healthcare AG | Novel compounds for the treatment and prevention of neurological complications of viral infections |
| JP2023061448A (en) * | 2021-10-20 | 2023-05-02 | リファインホールディングス株式会社 | Endoplasmic reticulum stress inhibitor, neurodegenerative disease preventing/improving agent, agent for prevention/progression prevention/improvement of dementia, and food product |
| WO2024075625A1 (en) * | 2022-10-02 | 2024-04-11 | リファインホールディングス株式会社 | Agent for preventing, agent for inhibiting progression, agent for improving, and food for visual field defect disorders, light-induced eye tissue disorders, and disorders related thereto |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS558351A (en) | 1978-07-05 | 1980-01-21 | Hitachi Ltd | Press machine |
| DE3032300A1 (en) | 1980-08-27 | 1982-04-01 | Alfred Ing. Wien Lohninger | Parenteral nutrition fatty emulsion - contg. fatty acid tri:glyceride(s), glycerol, carnitine or acyl-carnitine, phospholipid, and carrier or diluent |
| JPS5919775U (en) | 1982-07-26 | 1984-02-06 | ワイケイケイ株式会社 | Curtain wall insulation window |
| JPH02247125A (en) | 1989-03-17 | 1990-10-02 | Koken Kk | Inhibitor of malignant tumor cell multiplication |
| JP3558351B2 (en) | 1992-12-07 | 2004-08-25 | 邦郎 辻 | Immunosuppressants |
| DE19821003A1 (en) * | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | New dihydro-indazolone derivatives useful as antiasthmatic, antiallergic and neuroprotective agents and for treatment of inflammation and immune disorders |
| ES2323940T3 (en) | 2000-05-01 | 2009-07-28 | Accera, Inc. | USE OF MEDIUM CHAIN TRIGLICERIDS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE. |
| DE60123603T2 (en) | 2000-06-14 | 2007-08-16 | William Leslie Diss Porter | LIPID TO CHANGE THE DEFENSE SYSTEM |
| IL142535A0 (en) | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
| EA007322B1 (en) | 2001-04-18 | 2006-08-25 | Прометик Байосайенсиз, Инк. | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| CN1764446A (en) * | 2003-03-13 | 2006-04-26 | 康福玛医药公司 | Drug formulations having long and medium chain triglycerides |
| EP1628622A4 (en) | 2003-05-20 | 2008-12-17 | Baylor Res Inst | Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements |
| JP4334956B2 (en) * | 2003-09-18 | 2009-09-30 | 株式会社ノエビア | Cell activators, whitening agents, and antioxidants |
| CN101137369A (en) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | Formulations for ocular treatment |
| NZ575655A (en) | 2006-09-26 | 2012-06-29 | Baylor Res Inst | Nutrient sensor |
| EP1929995A1 (en) | 2006-12-04 | 2008-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anaplerotic therapy of Huntington disease and other polyglutamine diseases |
| KR100829729B1 (en) * | 2007-01-29 | 2008-05-15 | 한불화장품주식회사 | Skin agent composition containing an extract of ophiglossum vulgatum |
| MX338513B (en) | 2007-11-02 | 2016-04-20 | Prometic Pharma Smt Ltd | Medium-chain length fatty acids and glycerides as nephroprotection agents. |
| DE102008046227A1 (en) * | 2008-06-10 | 2009-12-17 | Ludwig-Maximilians-Universität München | High throughput method for analysis of fatty acid composition in plasma phosphoglycerides |
| DE102008057867A1 (en) | 2008-11-18 | 2010-05-20 | B. Braun Melsungen Ag | Fat emulsion for the artificial nutrition of severely ill intensive care patients |
| CN101879156B (en) | 2009-05-07 | 2013-01-30 | 上海医药工业研究院 | Medicinal composition and application thereof |
| ES2640777T3 (en) * | 2009-12-30 | 2017-11-06 | Baylor Research Institute | Anaplerotic therapy for Alzheimer's disease |
| WO2011085211A1 (en) * | 2010-01-08 | 2011-07-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid fumarate derivatives and their uses |
| US20130196937A1 (en) * | 2010-02-10 | 2013-08-01 | Oryza Oil & Fat Chemical Co., Ltd. | Age production inhibitor |
| US20110301238A1 (en) * | 2010-06-02 | 2011-12-08 | Borges Karin | Seizure related disorders and therapeutic methods thereof |
| KR20130041902A (en) | 2010-06-14 | 2013-04-25 | 베일러 리서치 인스티튜트 | Triheptanoin diet for adult polyglucosan body disease (apbd) treatment |
| KR101821441B1 (en) * | 2010-07-15 | 2018-01-23 | 하이브리제닉스 에스에이 | Formulations of 14-epi-analogues of vitamin d |
| WO2013031729A1 (en) | 2011-08-26 | 2013-03-07 | 国立大学法人大阪大学 | Prophylactic/therapeutic agent for cardiovascular complications of diabetes |
| CN102526643B (en) * | 2012-03-22 | 2013-09-11 | 常熟市虞山绿茶有限公司 | Chinese herbal medicine buccal tablet for treating dental ulcer |
| CN104955450A (en) | 2012-12-13 | 2015-09-30 | 达拉斯贝勒研究院 | Triheptanoin for the treatment of glucose transporter 1 deficiency |
| CN117502539A (en) * | 2013-08-02 | 2024-02-06 | 施韦特-莫迪国际公司 | Edible product comprising reconstituted plant material |
| EP3068492B1 (en) * | 2013-11-14 | 2020-01-08 | The University of Queensland | Neurodegenerative disorders and methods of treatment and diagnosis thereof |
| CN103641713B (en) * | 2013-11-15 | 2015-10-21 | 浙江大学 | The preparation method of monoglyceride derivative and application |
| WO2015110977A1 (en) | 2014-01-22 | 2015-07-30 | Rolexi Marketing (Pty) Ltd | Fatty acid composition and medicinal use thereof |
| CN104286296A (en) * | 2014-09-25 | 2015-01-21 | 王美华 | Cool tea |
| JP6406978B2 (en) | 2014-11-04 | 2018-10-17 | 株式会社シー・アクト | Fatty acid mixture |
| CN105267501A (en) * | 2015-11-04 | 2016-01-27 | 夏茂森 | Traditional Chinese medicine composition for treating poisonous snake bites |
| CN105381182A (en) * | 2015-11-20 | 2016-03-09 | 冯天寿 | Traditional Chinese medicine for treating chronic urticaria and application thereof |
| WO2017093060A1 (en) | 2015-12-04 | 2017-06-08 | Nestec S.A. | Method for improving cognition |
-
2017
- 2017-06-06 SG SG11201810580PA patent/SG11201810580PA/en unknown
- 2017-06-06 WO PCT/CN2017/087341 patent/WO2017211274A1/en unknown
- 2017-06-06 NZ NZ749389A patent/NZ749389A/en unknown
- 2017-06-06 KR KR1020197000135A patent/KR20190017873A/en not_active Application Discontinuation
- 2017-06-06 CN CN202311053636.8A patent/CN117298092A/en active Pending
- 2017-06-06 JP JP2018564968A patent/JP6872805B2/en active Active
- 2017-06-06 AU AU2017277005A patent/AU2017277005B2/en active Active
- 2017-06-06 US US16/307,663 patent/US11406616B2/en active Active
- 2017-06-06 EP EP17809713.5A patent/EP3468551A4/en active Pending
- 2017-06-06 TW TW106118787A patent/TWI749016B/en active
- 2017-06-06 CN CN201780036000.9A patent/CN110300581B/en active Active
- 2017-06-06 MX MX2018015188A patent/MX2018015188A/en unknown
- 2017-06-06 CA CA3026152A patent/CA3026152A1/en active Pending
-
2018
- 2018-12-07 CL CL2018003537A patent/CL2018003537A1/en unknown
-
2021
- 2021-04-13 JP JP2021067485A patent/JP2021113204A/en active Pending
-
2022
- 2022-06-30 US US17/810,044 patent/US20220362197A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3026152A1 (en) | 2017-12-14 |
| CL2018003537A1 (en) | 2019-05-03 |
| JP2021113204A (en) | 2021-08-05 |
| WO2017211274A1 (en) | 2017-12-14 |
| TWI749016B (en) | 2021-12-11 |
| CN117298092A (en) | 2023-12-29 |
| TW201801720A (en) | 2018-01-16 |
| KR20190017873A (en) | 2019-02-20 |
| MX2018015188A (en) | 2019-08-21 |
| CN110300581A (en) | 2019-10-01 |
| JP2019518034A (en) | 2019-06-27 |
| AU2017277005A1 (en) | 2019-01-17 |
| NZ749389A (en) | 2022-12-23 |
| EP3468551A1 (en) | 2019-04-17 |
| US20190255129A1 (en) | 2019-08-22 |
| AU2017277005B2 (en) | 2022-12-22 |
| US11406616B2 (en) | 2022-08-09 |
| JP6872805B2 (en) | 2021-05-19 |
| CN110300581B (en) | 2023-09-08 |
| US20220362197A1 (en) | 2022-11-17 |
| EP3468551A4 (en) | 2020-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810580PA (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201809627QA (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201903946SA (en) | Devices and methods for slurry generation | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809605PA (en) | Compositions for and method of treating acid-base disorders | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809237RA (en) | Oxaborole esters and uses thereof |